Prepropensity and postpropensity score-matched baseline characteristics
| Prematching | Postmatching | |||||
| TNFi* (n=4186) | Non-TNFi† (n=630) | Standardised difference | TNFi‡ (n=2372) | Non-TNFi§ (n=593) | Standardised difference | |
| Age (years), mean (SD) | 56.9 (12.7) | 62.7 (13.0) | –0.4476¶ | 61.0 (12.9) | 62.3 (12.8) | –0.1005¶ |
| Female, n (%) | 3202 (76.5) | 503 (79.8) | –0.0807 | 1821 (76.8) | 473 (79.8) | –0.0726 |
| White, n (%) | 3443 (82.7) | 511 (81.5) | 0.0783 | 1956 (82.8) | 483 (81.9) | 0.1025¶ |
| Duration of rheumatoid arthritis (years), mean (SD) | 7.1 (8.6) | 8.6 (9.7) | –0.1564¶ | 8.2 (9.3) | 8.7 (9.5) | –0.0602 |
| Rheumatoid factor positive, n (%) | 1862 (71.1) | 240 (69.8) | 0.0291 | 1032 (70.2) | 228 (70.4) | –0.0036 |
| Concomitant csDMARD, n (%) | 3485 (83.3) | 476 (75.6) | 0.1912¶ | 1851 (78.0) | 455 (76.7) | 0.0312 |
| Prednisone use, n (%) | 1312 (31.3) | 198 (31.4) | –0.0019 | 752 (31.7) | 185 (31.2) | 0.0109 |
| BMI, mean (SD) | 30.1 (7.2) | 29.6 (7.2) | 0.0668 | 30.0 (7.1) | 29.8 (7.3) | 0.0377 |
| CDAI score (0–76), mean (SD) | 20.4 (13.5) | 20.4 (13.2) | –0.0150 | 19.8 (13.2) | 20.1 (13.1) | –0.0256 |
| HAQ score (0–3), mean (SD) | 1.0 (0.6) | 1.1 (0.6) | –0.0744 | 1.1 (0.6) | 1.1 (0.6) | –0.0036 |
| Comorbidity history, n (%) | ||||||
| Serious infections | 631 (15.1) | 101 (16.0) | –0.0264 | 373 (15.7) | 95 (16.0) | –0.0081 |
| Cancer | 316 (7.5) | 97 (15.4) | –0.2481¶ | 289 (12.2) | 87 (14.7) | –0.0730 |
| Cardiovascular disease | 332 (7.9) | 69 (11.0) | –0.1035¶ | 238 (10.0) | 64 (10.8) | –0.0248 |
| Anaemia | 128 (3.1) | 29 (4.6) | –0.0806 | 84 (3.5) | 28 (4.7) | –0.0593 |
*Adalimumab (n=1464), etanercept (n=1322), certolizumab pegol (n=229), golimumab (n=139) and infliximab (n=1032).
†Abatacept (n=369), tocilizumab (n=53), rituximab (n=94), anakinra (n=14) and tofacitinib (n=100).
‡Adalimumab (n=759), etanercept (n=734), certolizumab pegol (n=155), golimumab (n=87) and infliximab (n=637).
§Abatacept (n=352), tocilizumab (n=49), rituximab (n=88), anakinra (n=11) and tofacitinib (n=93).
¶Standardised difference >0.1 or <–0.1.
BMI, body mass index; CDAI, Clinical Disease Activity Index; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; TNFi, tumour necrosis factor inhibitor.